Navigation Links
Renal sympathetic denervation improves physical and mental health in resistant hypertension
Date:8/27/2012

Munich, Germany August 26 2012: Renal sympathetic denervation improves anxiety, depression, quality of life and stress in patients with resistant hypertension, according to research presented at ESC Congress 2012 by Dr Denise Fischer from Saarland University Hospital.

Arterial hypertension is often associated with several psychological comorbidities, such as anxiety and panic disorders, leading to impaired quality of life. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension and has been shown to reduce local and whole-body sympathetic activity and blood pressure (BP).

The aim of the present study was to analyze quality of life, arousal level, anxiety and depression, sleeping quality, intensity of headache and stress tolerance in patients with resistant hypertension before and after RDN.

RDN was performed in 173 patients with resistant hypertension (BP 174/8823/13mmHg and taking a median of 5 antihypertensive drugs) aged 6310 years (53% male). Psychological status, intensity of headache, sleeping quality and stress tolerance were documented before and 3 months after RDN.

Patients rated their physical and mental state and arousal level on a 0-100% scale. Stress was induced by a multi tasking situation (Determination Task) and the total number of correct reactions, omissions and commission errors (responding to stimuli where it is not required) were recorded. Assessments were made of depression and anxiety using the Hospital Anxiety and Depression Scale (HADS) and of quality of life using the Short Form-12 Health Survey (SF-12). Insomnia and the level of regeneration achieved during sleep were assessed using a 0-100% scale and intensity of headache was measured by a visual analogous scale (VAS).

Three months after RDN was performed, office blood pressure decreased by 17/7 mmHg (p<0.01). In addition patients showed more correct reactions (p<0.0001) and less errors (p<0.05) in the multi tasking situation (Figure A shows the percentile rank (PR) score; the average percentile is 50%). Patients reported improvements in their physical state (from 55.6% to 67.2%; p<0.01), mental state (from 51.6% to 68.4%; p<0.05) and quality of life (p<0.05) (Figure B). Anxiety (p<0.0001) and depression (p<0.0001) scores decreased (Figure C). Arousal level was reduced from 49.9% to 38.9% (p<0.0001).

At baseline 32.2% of patients suffered from sleeping disorders and 60% suffered from headaches. Three months after RDN, sleeping quality improved (p<0.0001) and the intensity of headache decreased (p<0.0001) (Figure D).

"In patients with resistant hypertension overactivity of the sympathetic nervous system causes hyperarousal, leading to higher anxiety and stress levels," said Dr Fischer. "Renal denervation reduces office blood pressure and resting heart rate and does not impair psychological processes."

She added: "Renal denervation may have a positive effect on psychological processes, stress perception and processing as well as quality of life. It improves sleeping quality and may reduce the intensity of headache."

Future research should investigate long term effects of RDN on psychological processes, quality of life, rehospitalisation and mortality rates in a larger cohort of patients.


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Newborn Screening May Miss Adrenal-Gland Disorder
2. Broken heart syndrome protects the heart from adrenaline overload
3. Renal denervation gives better outcomes than drugs in advanced heart failure
4. Renal denervation treats resistant hypertension in real world patient populations
5. Clinical insight improves treatment with new lung cancer drug
6. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
7. Exercise improves quality of life during breast cancer treatment
8. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
9. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
10. Brief training program improves resident physicians empathy with patients
11. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Melbourne, FLA (PRWEB) , ... February 09, 2016 ... ... the team at Clevens Face and Body Specialists are delighted to welcome a ... Certified ARNP joins Clevens Face and Body Specialists as a nurse practitioner performing ...
(Date:2/9/2016)... ... February 09, 2016 , ... Center ... who are diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid ... applied behavior analysis (ABA) is key to providing effective treatment for individuals with ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, today announced ... to the cloud. Cirracore provides a secure VMware® vCloud Air based cloud ... Transformation Solutions (TSL Partners) provides a full range of services from planning, ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., ... introduction of the newly designed, innovative shoulder wrap. The newly designed shoulder ... for the injured arm and shoulder to promote faster healing. It is highly ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: ... 2015 fourth quarter and full year financial results on ... financial markets.  Company management will host a live audio ... p.m. GMT to discuss fourth quarter and full year ... update and guidance for 2016 financial results. ...
(Date:2/9/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQB: ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference which ... New York City . The Company,s presentation will ... pm by Gerald E. Commissiong , President & ...
(Date:2/9/2016)... "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: ... global market for blood monitoring & cardiac monitoring devices was valued ... US$ 24,830.1 million by 2019 at a CAGR of 6.8% from ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth of ...
Breaking Medicine Technology: